Right now, psilocybin and MDMA sit in the strictest category of controlled substances. The only realistic path to changing that is if the US drug regulator (FDA (the US Food and Drug Administration)) first approves one of them as a medicine — which would then force a legal reclassification automatically. Politicians won't touch this issue before that happens because the political risk is too high.
Status-quo prediction with strong structural support: scheduling votes carry asymmetric political risk before FDA acts, and no rescheduling bill has advanced past committee this Congress. Four agents (congresswoman, fda_reviewer, dea_officer, investor) converge; the sole dissent (veteran_advocate) reflects advocacy hope rather than legislative mechanics. Resolves FALSE if Congress passes, or DEA independently initiates, rescheduling of either substance before the resolve date absent an FDA approval trigger.